OptiBiotix Health Plc announced final revenue results for the year ended 30 November 2019. Total sales for the year were £808,000 with other income of £617,000, including, inter alia, income resulting from the partial disposal of SkinBioTherapeutics plc shares, bringing the total amount of income for the year ending 30 November 2019 to £1,426,522 against £541,614 in 2018.

The company anticipates further revenue growth in 2020 as existing deals contribute to full year revenues, partners continue to grow sales, the launch of SlimBiome® with Holland and Barrett and AlfaSigma's launch of Ezimega 3 containing LPLDL® in Italy contribute to 2020 sales and larger partners like Agropur and Akum commercialise products in home markets.